Charles River Laboratories International, Inc. $CRL Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 35.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,508 shares of the medical research company’s stock after selling 10,937 shares during the quarter. Russell Investments Group Ltd.’s holdings in Charles River Laboratories International were worth $2,936,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its stake in Charles River Laboratories International by 1,721.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company’s stock valued at $85,811,000 after acquiring an additional 538,792 shares in the last quarter. Nomura Holdings Inc. bought a new stake in Charles River Laboratories International during the 4th quarter valued at $56,820,000. SG Americas Securities LLC raised its stake in Charles River Laboratories International by 16,153.2% during the 1st quarter. SG Americas Securities LLC now owns 267,202 shares of the medical research company’s stock valued at $40,219,000 after acquiring an additional 265,558 shares in the last quarter. GAMMA Investing LLC raised its stake in Charles River Laboratories International by 24,226.8% during the 1st quarter. GAMMA Investing LLC now owns 210,427 shares of the medical research company’s stock valued at $31,673,000 after acquiring an additional 209,562 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in Charles River Laboratories International during the 4th quarter valued at $36,968,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on CRL shares. Cowen raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Wednesday, May 14th. Robert W. Baird lifted their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, May 8th. TD Cowen raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 target price on the stock in a research note on Wednesday, May 14th. Barclays lifted their target price on Charles River Laboratories International from $155.00 to $165.00 and gave the company an “equal weight” rating in a research note on Thursday, August 7th. Finally, Redburn Atlantic raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and cut their target price for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. Five investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $175.69.

Charles River Laboratories International Stock Up 4.5%

CRL opened at $161.5530 on Monday. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $230.02. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. The stock’s fifty day moving average is $157.67 and its 200-day moving average is $148.53. The company has a market capitalization of $7.95 billion, a PE ratio of -121.47, a P/E/G ratio of 5.16 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. During the same quarter in the previous year, the business earned $2.80 EPS. The company’s quarterly revenue was up .6% compared to the same quarter last year. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Activity

In other news, EVP Joseph W. Laplume sold 800 shares of the business’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares of the company’s stock, valued at $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).